Bristol Myers Squibb Announces Topline Results from Phase 3 INDEPENDENCE Trial for Reblozyl® (luspatercept-aamt) in Adult Patients with Myelofibrosis-Associated Anemia – Bristol Myers Squibb

1. Bristol Myers Squibb Announces Topline Results from Phase 3 INDEPENDENCE Trial for Reblozyl® (luspatercept-aamt) in Adult Patients with Myelofibrosis-Associated Anemia  Bristol Myers Squibb
2. Bristol Myers Squibb’s Reblozyl misses primary endpoint in myelofibrosis trial  Investing.com
3. Bristol Myers’ drug fails to meet main goal of late-stage anemia trial  TradingView

Continue Reading